Iacovelli R.; Farcomeni A.; Sternberg C.N.; Carteni G.; Milella M.; Santoni M.; Cerbone L.; Di Lorenzo G.; Verzoni E.; Ortega C.; Sabbatini R.; Ricotta R.; Messina C.; Lorusso V.; Atzori F.; De Vincenzo F.; Sacco C.; Boccardo F.; Valduga F.; Massari F.; Baldazzi V.; Cinieri S.; Mosca A.; Maria Ruggeri E.; Berruti A.; Procopio G., Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma, «THE JOURNAL OF UROLOGY», 2015, 193, pp. 1905 - 1910 [Scientific article]
Santoni M.; Buti S.; Conti A.; Porta C.; Procopio G.; Sternberg C.N.; Bracarda S.; Basso U.; De Giorgi U.; Rizzo M.; Derosa L.; Ortega C.; Massari F.; Milella M.; Bersanelli M.; Cerbone L.; Muzzonigro G.; Burattini L.; Montironi R.; Santini D.; Cascinu S., Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy, «TARGETED ONCOLOGY», 2015, 10, pp. 517 - 522 [Scientific article]
Massari F.; Bria E.; Ciccarese C.; Munari E.; Modena A.; Zambonin V.; Sperduti I.; Artibani W.; Cheng L.; Martignoni G.; Tortora G.; Brunelli M., Prognostic value of beta-tubulin-3 and c-Myc in muscle invasive urothelial carcinoma of the bladder, «PLOS ONE», 2015, 10, Article number: e0127908 , pp. 0127908 - 0127920 [Scientific article]
Bria E.; Massari F.; Maines F.; Pilotto S.; Bonomi M.; Porta C.; Bracarda S.; Heng D.; Santini D.; Sperduti I.; Giannarelli D.; Cognetti F.; Tortora G.; Milella M., Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2015, 93, pp. 50 - 59 [Scientific article]
Santoni M.; Massari F.; Cascinu S., Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients, «CELLULAR & MOLECULAR IMMUNOLOGY», 2015, 12, pp. 122 - 124 [Scientific article]
Santoni M.; Conti A.; Andrikou K.; Bittoni A.; Lanese A.; Pistelli M.; Pantano F.; Vincenzi B.; Armento G.; Massari F.; Tonini G.; Cascinu S.; Santini D., Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2015, 96, pp. 206 - 219 [Scientific article]
Santoni M.; Conti A.; Piva F.; Massari F.; Ciccarese C.; Burattini L.; Cheng L.; Lopez-Beltran A.; Scarpelli M.; Santini D.; Tortora G.; Cascinu S.; Montironi R., Role of STAT3 pathway in genitourinary tumors, «FUTURE SCIENCE OA», 2015, 1, Article number: FSO15 , pp. 1 - 9 [Scientific article]
Caffo O.; De Giorgi U.; Fratino L.; Lo Re G.; Basso U.; D'Angelo A.; Donini M.; Verderame F.; Ratta R.; Procopio G.; Campadelli E.; Massari F.; Gasparro D.; Macrini S.; Messina C.; Giordano M.; Alesini D.; Zustovich F.; Fraccon A.P.; Vicario G.; Conteduca V.; Maines F.; Galligioni E., Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme, «BJU INTERNATIONAL», 2015, 115, pp. 764 - 771 [Scientific article]
Bracarda S.; Iacovelli R.; Boni L.; Rizzo M.; Derosa L.; Rossi M.; Galli L.; Procopio G.; Sisani M.; Longo F.; Santoni M.; Morelli F.; Di Lorenzo G.; Altavilla A.; Porta C.; Camerini A.; Escudier B.; Martignetti A.; Ricotta R.; Gasparro D.; Sabbatini R.; Ceresoli G.L.; Mosca A.; Santini D.; Caserta C.; Cavanna L.; Massari F.; Sava T.; Boni C.; Verzoni E.; Carteni G.; Hamzaj A., Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis, «ANNALS OF ONCOLOGY», 2015, 26, pp. 2107 - 2113 [Scientific article]
Santoni M.; Conti A.; Porta C.; Procopio G.; Sternberg C.N.; Basso U.; De Giorgi U.; Bracarda S.; Rizzo M.; Ortega C.; Massari F.; Iacovelli R.; Derosa L.; Masini C.; Milella M.; Di Lorenzo G.; Atzori F.; Pagano M.; Buti S.; De Vivo R.; Mosca A.; Rossi M.; Paglino C.; Verzoni E.; Cerbone L.; Muzzonigro G.; Falconi M.; Montironi R.; Burattini L.; Santini D.; Cascinu S., Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma, «THE JOURNAL OF UROLOGY», 2015, 193, pp. 41 - 47 [Scientific article]
Ortolani S.; Ciccarese C.; Cingarlini S.; Tortora G.; Massari F., Suppression of mTOR pathway in solid tumors: Lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives, «FUTURE ONCOLOGY», 2015, 11, pp. 1809 - 1828 [Scientific article]
Santoni M.; Conti A.; Partelli S.; Porta C.; Sternberg C.N.; Procopio G.; Bracarda S.; Basso U.; De Giorgi U.; Derosa L.; Rizzo M.; Ortega C.; Massari F.; Iacovelli R.; Milella M.; Di Lorenzo G.; Buti S.; Cerbone L.; Burattini L.; Montironi R.; Santini D.; Falconi M.; Cascinu S., Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors, «ANNALS OF SURGICAL ONCOLOGY», 2015, 22, pp. 2094 - 2100 [Scientific article]
Massari F.; Ciccarese C.; Santoni M.; Lopez-Beltran A.; Scarpelli M.; Montironi R.; Cheng L., Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma, «EXPERT REVIEW OF ANTICANCER THERAPY», 2015, 15, pp. 1367 - 1369 [Scientific article]
Massari F.; Santoni M.; Ciccarese C.; Santini D., The immunocheckpoints in modern oncology: The next 15 years, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2015, 15, pp. 917 - 921 [Scientific article]
Santoni M.; Piva F.; Scarpelli M.; Cheng L.; Lopez-Beltran A.; Massari F.; Iacovelli R.; Berardi R.; Santini D.; Montironi R., The origin of prostate metastases: emerging insights, «CANCER METASTASIS REVIEWS», 2015, 34, pp. 765 - 773 [Scientific article]
